Company Analysis
Sign in

Vertex Pharmaceuticals Incorporated (VRTX)

Nasdaq: VRTX · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 1995
Full chart Alerts Compare
Grade7.0
◀ Past 7.3● Present 7.6▶ Future 5.9
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts in thousands. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016
Report filedFeb 13, 2026Feb 13, 2025Feb 15, 2024Feb 10, 2023Feb 9, 2022Feb 11, 2021Feb 13, 2020Feb 13, 2019Feb 15, 2018Feb 23, 2017
Revenue12,001,30011,020,1009,869,2008,930,7007,574,4006,205,700r4,162,800r3,047,5972,488,6521,702,177
For lenders
Net interest income··-44,100-54,800-61,500-58,200-58,500···
Cost of revenue1,651,3001,530,5001,262,2001,080,300904,200736,300547,800r409,539275,119210,460
Research and development3,909,5003,630,3003,162,9002,540,3001,937,8001,644,9001,754,500r1,416,4761,324,6251,047,690
Selling, general and administrative1,753,1001,464,3001,136,600944,700840,100770,500r658,500r557,616496,079432,829
Total costs and expenses7,828,00011,253,0006,037,2004,623,3004,792,3003,349,400r2,965,300r2,412,4472,365,4091,692,241
Operating income4,173,300-232,9003,832,0004,307,4002,782,1002,856,300r1,197,500r635,150123,2439,936
Interest expense13,30030,60044,10054,800·58,15158,50272,47169,298·
Interest and investment income490,900598,100614,700144,6004,90022,200r63,700r38,35211,748·
Interest income (expense), net·······-34,119-57,550-81,432
Other income (expense), net-7,700-86,100-22,800-164,8004,900296,600r192,200r-790-81,3824,130
Income before income taxes4,643,200248,5004,379,8004,232,4002,730,4003,116,9001,394,900600,241-15,689-67,366
Income tax expense690,000784,100760,200910,400388,300405,200r218,100r-1,486,862-107,32416,665
Income from continuing operations·········-112,052
Income from discontinued operations·········0
Net income including non-controlling interests·····2,711,6471,176,8102,087,10391,635-84,031
Net income to non-controlling interests·····00-9,793-171,84928,021
Net income3,953,200-535,6003,619,6003,322,0002,342,1002,711,700r1,176,800r2,096,896263,484-112,052
Net income to common shareholders·····2,711,6471,176,8102,096,395263,191-112,052
Earnings per share, basic15.46-2.0814.0512.979.0910.444.588.241.06-0.46
Earnings per share, diluted15.32-2.0813.8912.829.0110.294.518.091.04-0.46
Weighted average shares, basic255,700257,900257,700256,100257,700259,800r256,700r254,292248,858244,685
Weighted average shares, diluted258,000257,900260,500259,100259,900263,400r260,700r259,185253,225244,685
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:Revenues
Net interest income interest earned less interest paidus-gaap:InterestIncomeExpenseNet
Cost of revenue what it cost to make or buy what it soldus-gaap:CostOfGoodsAndServicesSold
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
us-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative the cost of selling and of running the companyus-gaap:SellingGeneralAndAdministrativeExpense
Total costs and expenses every operating cost, the cost of revenue includedus-gaap:CostsAndExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpenseNonoperating
us-gaap:InterestExpense
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterestAndDividend
Interest income (expense), net interest earned less interest paid, outside the businessus-gaap:InterestIncomeExpenseNonoperatingNet
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Income from continuing operations profit from the businesses it keepsus-gaap:IncomeLossFromContinuingOperations
Income from discontinued operations profit or loss from businesses it sold or closedus-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income to non-controlling interests the share that belongs to minority holdersus-gaap:NetIncomeLossAttributableToNoncontrollingInterest
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton VRTX · research, not advice